how to get off tirzepatide Taking a Break from Tirzepatide: Safety Guidelines how to get off tirzepatide

Symptoms of Tinnitus Not only does tinnitus cause subtle ringing sounds, but it may also cause the patient to hear whistling or buzzing in the ears

Urgent medical attention: Call 999 or go to A&E immediately if you experience: Severe allergic reactions (difficulty breathing, facial swelling, widespread rash) Symptoms of pancreatitis (severe, persistent abdominal pain radiating to the back, often with nausea and vomiting) Signs of severe hypoglycaemia if taking other diabetes medications (confusion, loss of consciousness) Contact your GP, diabetes specialist or NHS 111 promptly if you experience: Signs of infection at the injection site (increasing pain, redness, swelling, warmth, or discharge) Persistent severe nausea, vomiting, or diarrhoea, especially with signs of dehydration Symptoms of gallbladder problems (sudden pain in upper abdomen, especially on the right side, fever, yellowing of skin/eyes) Visual changes, particularly if you have diabetic retinopathy Moderate hypoglycaemia symptoms (sweating, tremor, rapid heartbeat, hunger) Seek advice before your next appointment if: You are pregnant, planning pregnancy, or breastfeeding You need guidance on managing your medication during illness You have questions about side effects or dosage You're unsure about injection technique with your pre-filled pen Medication sourcing and safety: In the UK, tirzepatide should only be obtained through legitimate, regulated channels such as NHS prescriptions or registered private healthcare providers

Tirzepatides long-term side effects affect around 5% of patients and include: Nausea Vomiting Diarrhea Decreased appetite Hair loss Dizziness Abdominal pain, indigestion 1 to 7% of people have an injection site reaction, such as itching or hives, but serious reactions are rare

[7] Two trials in the phase 3 TRIUMPH program reached primary completion in April 2026: TRIUMPH-1, a master protocol in adults with obesity or overweight, and TRIUMPH-3, in participants with severe obesity and established cardiovascular disease